QQ客服 官方微博 反馈留言

	Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
	Satoh, Taroh; Xu, Rui-Hua; Chung, Hyun Cheol; Sun, Guo-Ping; Doi, Toshihiko; Xu, Jian-Ming; Tsuji, Akihito; Omuro, Yasushi; Li, Jin; Wang, Jin-Wan
	2014
卷号	32期号:19页码:2039-U89
ISSN号	0732-183X
DOI	10.1200/JCO.2013.53.6136
URL标识	查看原文
收录类别	SCIE ; PUBMED ; ESI高被引论文 ; ESI热点论文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6683820
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Satoh, Taroh,Xu, Rui-Hua,Chung, Hyun Cheol,et al. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study[J],2014,32(19):2039-U89.
APA	Satoh, Taroh.,Xu, Rui-Hua.,Chung, Hyun Cheol.,Sun, Guo-Ping.,Doi, Toshihiko.,...&Bang, Yung-Jue.(2014).Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study.,32(19),2039-U89.
MLA	Satoh, Taroh,et al."Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study".32.19(2014):2039-U89.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。